Clinical trial
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of…
NCT00467402 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00467402 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder |
| Official title | A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | agomelatine, placebo |
| Enrollment | 644 |
| Start date | Apr 1, 2007 |
| Primary completion | Sep 1, 2009 |
| First posted | Apr 30, 2007 |
| Last update posted | Dec 23, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: